FHND5071: a selective RET inhibitor with unique pharmacokinetic profile

被引：1
|
作者：
Zhu, Yongqiang
Wang, Jia
Shang, Minghong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB330
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FHND5071
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor
    Han, Yiran
    Wen, Tiantian
    Wang, Jia
    Shi, Jinmiao
    Zhu, Yongqiang
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2023, 48 (05) : 595 - 614
  • [2] Preclinical Pharmacokinetics and in vitro Metabolism of FHND5071, a Novel Selective RET Kinase Inhibitor
    Yiran Han
    Tiantian Wen
    Jia Wang
    Jinmiao Shi
    Yongqiang Zhu
    European Journal of Drug Metabolism and Pharmacokinetics, 2023, 48 : 595 - 614
  • [3] Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor
    Omura, Koichi
    Miyata, Kengo
    Kobashi, Seiichi
    Ito, Azusa
    Fushimi, Masahiko
    Uda, Junichiro
    Sasaki, Tomomitsu
    Iwanaga, Takashi
    Ohashi, Tetsuo
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (03) : 313 - 320
  • [4] Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat
    Frouni, Imane
    Bedard, Dominique
    Bourgeois-Cayer, Elodie
    Hamadjida, Adjia
    Gaudette, Fleur
    Beaudry, Francis
    Huot, Philippe
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2023, 396 (05) : 1053 - 1060
  • [5] Pharmacokinetic profile of bitopertin, a selective GlyT1 inhibitor, in the rat
    Imane Frouni
    Dominique Bédard
    Élodie Bourgeois-Cayer
    Adjia Hamadjida
    Fleur Gaudette
    Francis Beaudry
    Philippe Huot
    Naunyn-Schmiedeberg's Archives of Pharmacology, 2023, 396 : 1053 - 1060
  • [6] Selpercatinib: First approved selective RET inhibitor
    Oliveira, Larissa C. B.
    Mulligan, Lois M.
    CELL, 2023, 186 (08) : 1517 - 1517
  • [7] Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
    Gouda, Mohamed A.
    Subbiah, Vivek
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [8] mNSCLC First highly selective RET Inhibitor approved
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [9] Delivery of a potent, selective, and efficacious RET inhibitor for the treatment of RET-driven lung adenocarcinoma
    Watson, Mandy
    Newton, Rebecca
    Acton, Ben
    Small, Helen
    Begum, Habiba
    Hitchin, Samantha
    Kelly, Paul
    Ogilvie, Donald
    Waddell, Ian
    Jordan, Allan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] Characterization of a Novel, Highly Potent and Selective RET Inhibitor with Antitumor Efficacy in RET Dependent Models
    Ardini, E.
    Amboldil, N.
    Avanzi, N.
    Banfi, P.
    Cristiani, C.
    Donati, D.
    Galvani, A.
    Isacchi, A.
    Pesenti, E.
    Menichincheri, M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 94 - 95
12345